Drug–Drug Interaction Studies Look Beyond CYP Activity
Genetic Engineering & Biotechnology News
Most drug–drug interaction (DDI) studies take place in the laboratory, where scientists introduce an experimental drug into cell culture, checking for its ability to induce or inhibit drug-metabolizing cytochrome P450 (CYP) enzymes. These in vitro studies investigate how a drug is metabolized, how it may inhibit the metabolism of other drugs, and how it may impact enzymes and other cellular processes. The goal of these in vitro studies is to predict whether a drug is likely to be a “perpetrator” or a “victim” of DDI effects.